Pulmonary Arterial Hypertension

As a specialized cardiovascular contract research organization, SCIRENT is dedicated to pioneering research and clinical trials in cardiovascular health. SCIRENT stands at the forefront of groundbreaking research, focusing on cardiovascular conditions like Pulmonary Arterial Hypertension (PAH).

Insightful summary of Pulmonary Arterial Hypertension for clinical research

Understanding Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension (PAH) is a progressive condition characterized by elevated blood pressure in the pulmonary blood vessels, leading to increased workload on the heart. This results in debilitating symptoms such as shortness of breath, chest pain, and fatigue.

PAH is a significant concern, affecting individuals of all ages. The impact on patients’ lives is profound, limiting their physical activity and diminishing their overall quality of life. Understanding the prevalence and gravity of PAH is crucial for driving innovative research.

The current landscape of PAH treatment involves various medications aimed at managing symptoms and improving quality of life. However, there is a need for innovative research to develop more effective therapies, address the underlying causes, and ultimately improve patient outcomes.

Types of PAH

According to the World Health Organization, there are five types of PAH: Idiopathic, Inherited, Lung or Heart disease-related forms, and Pulmonary Hypertension Due to Chronic Blood Clots in the Lungs.

Primary or Idiopathic Pulmonary Arterial Hypertension is characterized by elevated pressures in the pulmonary circulation without any discernible cause. The heart's right ventricle must work harder to pump blood at a higher pressure through the pulmonary vessels, which may ultimately lead to right heart failure. Due to its elusive origins, this subtype poses a significant challenge for diagnosis and treatment.

Primary or Idiopathic Pulmonary Arterial Hypertension is characterized by elevated pressures in the pulmonary circulation without any discernible cause. The heart's right ventricle must work harder to pump blood at a higher pressure through the pulmonary vessels, which may ultimately lead to right heart failure. Due to its elusive origins, this subtype poses a significant challenge for diagnosis and treatment.

Group 3 relates to pulmonary hypertension due to chronic pulmonary diseases. In most cases, the underlying cause is chronic obstructive pulmonary disease (COPD), where the lung airways narrow and make it harder to exhale (e.g., emphysema). Other reasons may be interstitial lung disease, pulmonary fibrosis, sleep apnea, or rare lung diseases. The arteries in the lungs tighten, especially in those regions of the lung receiving less oxygen. Other vessels are tightened, which leads to elevated blood pressure throughout the lungs.

Pulmonary hypertension group 4 is called chronic thromboembolic pulmonary hypertension (CTEPH). This condition results from multiple blood clots (pulmonary embolism) that have occurred and/or if a blood clots in the lungs are not being dissolved. This ultimately leads to a blockage of normal blood flow through the lungs. In some cases, CTEPH may be treated through surgery (pulmonary thromboendarterectomy) to remove the blood clots.

Group 5 includes multiple that have in common that PAH is secondary to other diseases e.g. metabolic or immunological conditions.

In addition various genetic alterations may lead to PAH. Specific genes, notably BMPR2, play a crucial role in familial PAH. BMPR2 encodes a protein found on the surface of pulmonary artery cells, and mutations in this gene are linked to an increased risk of developing hereditary PAH. As our understanding of these genetic factors expands, there is promising potential to enhance treatment strategies and genetic counseling for affected families.

The Role of Clinical Research in Advancing PAH Treatment

Clinical trials are pivotal in advancing our understanding of PAH, providing a platform to test new treatments and interventions. These trials are essential for shaping the future of PAH management. SCIRENT offers extensive expertise in designing and conducting cardiovascular research, specifically focusing on PAH.

SCIRENT boasts a proven track record in conducting cardiovascular research, particularly in the field of PAH. Our success stories underscore our commitment to driving meaningful outcomes and advancing the understanding of this complex condition. 

Advantages of Partnering with SCIRENT

Efficiency, Data Quality, and Regulatory Compliance
Choosing SCIRENT as a partner in PAH research guarantees efficiency, unparalleled data quality, and unwavering regulatory compliance. We prioritize the highest standards in every aspect of our research endeavors.

Personalized Approach and Flexibility
SCIRENT takes pride in its personalized approach and flexibility. We understand that every research project is unique, and our commitment is to tailor our services to meet the specific needs of our clients.

Are you interested in working with us?

Together, let’s advance research, shape the future of PAH treatment, and make a lasting impact on cardiovascular healthcare. Connect with SCIRENT today and be a part of transformative research in Pulmonary Arterial Hypertension.

Thank you. Your data was submitted successfully.

We will get in touch shortly.

Thank you for your application.

We will get in touch shortly.